CG347B

Cat. No.:	HY-135890
CAS No.:	1598426-03-9
Molecular Formula:	$C_{16}H_{17}N_3O_2$
Molecular Weight:	283.33
Target:	HDAC
Pathway:	Cell Cycle/DNA Damage; Epigenetics
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 250 mg/mL (882.36 mM; Need ultrasonic)

Preparing Stock Solutions

Concentration \ Solvent \ Mass	1 mg	5 mg	10 mg
1 mM	3.5295 mL	17.6473 mL	35.2945 mL
5 mM	0.7059 mL	3.5295 mL	7.0589 mL
10 mM	0.3529 mL	1.7647 mL	3.5295 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 6.25 mg/mL (22.06 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

CG347B is a selective HDAC6 inhibitor, also involves in synthesis of other metalloenzyme inhibitors. HDAC6 inhibitors can be used for oncology, immunology, and neurology research[1][2].

IC_{50} & Target

HDAC6

In Vitro

HtrA1 is identified as a Cisplatin (HY-17394, CDDP) resistance-related gene in NSCLC cells, while CG347B shows no effect on normalized mRNA expression or protein level of HtrA1 in NCI-H460 (CDDP-resistant) cells[1].
CG347B (200 nM; 48 h) slightly rescues the Foxp3 expression inhibition induced by IL-4 (15 ng/mL), indicating a potential inhibition happens on histone deacetylation in naive $CD4^+$ T cells from WT B6 mice cultured under Treg-polarizing conditions (for 1-3 d)[3].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Mol Cancer. 2020 Sep 2;19(1):134.
- Cell Death Dis. 2021 May 18;12(6):501.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Wang W, et al. Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer. Mol Cancer. 2020 Sep 2;19(1):134.

[2]. Cui J, et al. IL-4 inhibits regulatory T cells differentiation by HDAC9-mediated epigenetic regulation. Cell Death Dis. 2021 May 18;12(6):501.

[3]. Christopher M. YATES. Metalloenzyme inhibitor compounds. WO2018165520A1.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA